Showing 1765 results
-
Press release /Novartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
-
Press release /Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
-
Story /Survey results highlight the need for concerted action to guard against a fresh upsurge in the disease.
-
Press release /Innovative AcrySof® IQ PanOptix® Toric intraocular lens (IOL) extends Alcon's trifocal PanOptix® IOL portfolio to a wider range of patients CE-marked in November 2016, this IOL offers…
-
Press release /Pivotal overall survival data for investigational compound PKC412 (midostaurin) in adults with newly diagnosed FLT3-mutated acute myeloid leukemia Presentations highlight new CTL019 data in…
-
Press release /Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyx® at two years had no radiographic progression in the spine or joints, respectively[1],[2] …
-
Press release /New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months1Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of…
-
Press release /New analysis shows 94% of patients on Cosentyx® regained PASI 75, with up to 80% of patients regaining PASI 90 to 100 after only 16 weeks of retreatment[1] Cosentyx has shown superior and…
-
Press release /New patient preference survey confirms that patients value clear skin the most, but expect additional benefits from their treatment, such as proven long-term efficacy and safety data and no…
-
Press release /New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…